speb/financial-data huggingface dataset:
Financial ratios for SHILPAMED.NS — annual report dated 2024-03-31
Total revenue: 138098453.05192468
Gross profit: 89075536.63508815
Operating income: 16052320.422112962
Net income: 3832018.2276052283
Capital expenditures: 20681376.66386857
Operating cash flow: 16389135.387936203
Depreciation & amortization: 12935591.797577647
Net tangible assets: 155130267.41815564
Owner earnings: -3913766.638685692
Return on net tangible assets (%): -2.522890409346155
Capex to operating income (%): 128.83730277012677
Buffett classification: The Gruesome
Stock price: 2.759117082533589
P/E ratio: 140.82217189655128
Shares outstanding: 195581816
Book value: 215848051.32509893
P/B ratio: 2.500060233324851
Market cap (USD): 539633129.5585413
Debt to equity: 0.5207839698828345
Current ratio: 1.263346312208707
Quick ratio: 0.7660369562014139
Effective tax rate (%): 41.194721451876774
Interest coverage ratio: 1.5990269203570269
COGS to revenue (%): 35.431993490812374
R&D to revenue (%): 2.689225366727944
SG&A to revenue (%): 2.5364557056555084
Free cash flow (dilution-adjusted): -5743074.709197746
Buyback yield (%): 0
Retained earnings: 123971171.60330975
Inventory turnover: 1.182959289196792
Receivables turnover: 2.9374218043568923
Capitalized R&D asset: 10117053.746900747
ROCI (R&D-adjusted, %): 4.738228063782479
Rosenberg metric: 2.132438923921559
FCF margin (%): -4.158681420593729
Revenue growth (%): 8.6580297326534
Rule of 40 score: 4.499348312059671
Financial ratios for SHILPAMED.NS — quarterly report dated 2024-09-30
Capital expenditures: 0
Net tangible assets: 215381318.68131867
Buffett classification: The Gruesome
Stock price: 4.852603917821309
Shares outstanding: 195581816
Book value: 277016829.90922123
P/B ratio: 3.4260773502000634
Market cap (USD): 949081086.5762063
Debt to equity: 0.21153604440939572
Current ratio: 1.7372506646314163
Quick ratio: 1.0768569941308588
Buyback yield (%): 0
Capitalized R&D asset: 0
Rule of 40 score: 0
Financial ratios for SHILPAMED.NS — annual report dated 2025-03-31
Total revenue: 150389291.5595043
Gross profit: 102412906.24269347
Operating income: 28505962.122983396
Net income: 9153612.345101707
Capital expenditures: 28487257.423427634
Operating cash flow: 15462941.314005142
Depreciation & amortization: 13209025.017535655
Net tangible assets: 211315010.52139348
Owner earnings: -6124620.060790271
Return on net tangible assets (%): -2.898336490947109
Capex to operating income (%): 99.93438320209974
Buffett classification: The Gruesome
Stock price: 3.866262107597153
P/E ratio: 82.60897836038266
Shares outstanding: 195581816
Book value: 276327051.6717325
P/B ratio: 2.7365057440490643
Market cap (USD): 756170564.1358385
Debt to equity: 0.24865524480755102
Current ratio: 1.461918460732074
Quick ratio: 0.9458830355476942
Effective tax rate (%): 36.00098095315949
Interest coverage ratio: 2.158067085582795
COGS to revenue (%): 31.90146374073988
R&D to revenue (%): 3.7602823317242295
SG&A to revenue (%): 3.0802064628467933
Free cash flow (dilution-adjusted): -13024316.109422492
Buyback yield (%): 0
Retained earnings: 128254442.36614448
Inventory turnover: 1.179526666028603
Receivables turnover: 2.918162689220199
Capitalized R&D asset: 10116954.908521079
ROCI (R&D-adjusted, %): 9.12394454083429
Rosenberg metric: 3.59132057521088
FCF margin (%): -8.660401265517752
Revenue growth (%): 8.90005516785789
Rule of 40 score: 0.2396539023401374
Financial ratios for SHILPAMED.NS — quarterly report dated 2025-03-31
Total revenue: 38674304.41898527
Gross profit: 26458966.56534954
Operating income: 7566050.970306288
Net income: 1696282.4409632918
Capital expenditures: 0
Depreciation & amortization: 1693944.3535188215
Net tangible assets: 211315010.52139348
Owner earnings: 3390226.7944821133
Return on net tangible assets (%): 1.6043473608983814
Capex to operating income (%): 0
Buffett classification: The Great
Stock price: 3.866262107597153
P/E ratio: 111.44526198514755
Shares outstanding: 195581816
Book value: 275255284.0776245
P/B ratio: 2.7471609370543146
Market cap (USD): 756170564.1358385
Debt to equity: 0.24962343923979513
Current ratio: 1.461918460732074
Quick ratio: 0.9458830355476942
Effective tax rate (%): 5.0425671250818604
Interest coverage ratio: 2.248002778742619
COGS to revenue (%): 31.585152046430082
Buyback yield (%): 0
Retained earnings: 128254442.36614448
Inventory turnover: 0.3003210149694893
Receivables turnover: 0.750438485458071
Capitalized R&D asset: 0
ROCI (R&D-adjusted, %): 2.454792206125776
Rule of 40 score: 0
Financial ratios for SHILPAMED.NS — quarterly report dated 2025-06-30
Total revenue: 37614954.36461503
Gross profit: 28299953.19447695
Operating income: 7338579.452375381
Net income: 5486262.57898432
Capital expenditures: 0
Depreciation & amortization: 3384074.4207816524
Owner earnings: 8870336.999765974
Capex to operating income (%): 0
Buffett classification: The Great
Stock price: 5.2040720805055
P/E ratio: 46.380475480659314
Shares outstanding: 195581816
Market cap (USD): 1017821868.1001639
Effective tax rate (%): 5.434449374747882
Interest coverage ratio: 3.339270121185015
COGS to revenue (%): 24.764090047390415
Buyback yield (%): 0
Capitalized R&D asset: 0
Revenue growth (%): -2.739157355989066
Rule of 40 score: -2.739157355989066
Financial ratios for SHILPAMED.NS — quarterly report dated 2025-09-30
Total revenue: 41710124.01352875
Gross profit: 29816426.155580606
Operating income: 8845264.937993236
Net income: 4968060.879368658
Capital expenditures: 0
Depreciation & amortization: 3362209.6956031565
Net tangible assets: 206136381.05975196
Owner earnings: 8330270.574971815
Return on net tangible assets (%): 4.0411452515784445
Capex to operating income (%): 0
Buffett classification: The Great
Stock price: 4.245772266065389
P/E ratio: 68.34192936553323
Shares outstanding: 195581816
Book value: 274917767.7564825
P/B ratio: 3.020524489545014
Market cap (USD): 830395850.119504
Debt to equity: 0.24328471943193758
Current ratio: 1.3568316979373751
Quick ratio: 0.7867291939868075
Effective tax rate (%): 31.60498962435026
Interest coverage ratio: 5.007499361756446
COGS to revenue (%): 28.515134249158308
Buyback yield (%): 0
Inventory turnover: 0.23714215838114897
Receivables turnover: 0.8666788011931192
Capitalized R&D asset: 0
ROCI (R&D-adjusted, %): 2.8900158484443015
Revenue growth (%): 10.887078605008513
Rule of 40 score: 10.887078605008513
Financial ratios for SHILPAMED.NS — quarterly report dated 2025-12-31
Total revenue: 45641829.118859306
Gross profit: 30790186.03096803
Operating income: 9350128.105157625
Net income: 4966269.35501838
Capital expenditures: 0
Depreciation & amortization: 3382466.3027737555
Owner earnings: 8348735.657792136
Capex to operating income (%): 0
Buffett classification: The Great
Stock price: 3.5774757714158403
P/E ratio: 40.8771576396412
Shares outstanding: 195581816
Market cap (USD): 699689208.0695109
Effective tax rate (%): 26.73823769623011
Interest coverage ratio: 7.85786103465708
COGS to revenue (%): 32.53954404240681
Buyback yield (%): 0
Capitalized R&D asset: 0
Revenue growth (%): 9.426260885859033
Rule of 40 score: 9.426260885859033
Financial ratios for SHIVATEX.NS — annual report dated 2022-03-31
Capital expenditures: 0
Buffett classification: The Gruesome
Stock price: 2.6536990636951074
Shares outstanding: 12962713
Market cap (USD): 34399139.351048395
Buyback yield (%): 0
Retained earnings: 7717301.859422392
Capitalized R&D asset: 0
Rule of 40 score: 0
Financial ratios for SHIVATEX.NS — annual report dated 2023-03-31
Total revenue: 49950401.948842876
Gross profit: 9501644.336175397
Operating income: -575225.3349573691
Net income: -808769.7929354446
Capital expenditures: 616930.5724725944
Operating cash flow: 8182168.08769793
Depreciation & amortization: 1718915.9561510354
Net tangible assets: 15760621.193666263
Owner earnings: 293215.5907429963
Buffett classification: The Gruesome
Stock price: 1.4546894031668698
Shares outstanding: 12962713
Book value: 16335213.154689401
P/B ratio: 1.1543602803848425
Market cap (USD): 18856721.237393424
Debt to equity: 0.7774809282682176
Current ratio: 1.0453443615285976
Quick ratio: 0.43425844584058804
Interest coverage ratio: -0.387597153714206
COGS to revenue (%): 80.97784208842486
SG&A to revenue (%): 2.3526138474023446
Free cash flow (dilution-adjusted): 4827600.487210719
Buyback yield (%): 0
Retained earnings: 6098124.2387332525
Inventory turnover: 5.744906149987025
Receivables turnover: 18.11860138377117
Capitalized R&D asset: 0
ROCI (R&D-adjusted, %): -2.2100848869897205
FCF margin (%): 9.664788067481311
Rule of 40 score: 9.664788067481311
Financial ratios for SHIVATEX.NS — annual report dated 2024-03-31
Total revenue: 40101486.98884758
Gross profit: 9862057.800695527
Operating income: -282515.88919534715
Net income: -1291114.0424511333
Capital expenditures: 292744.93344525725
Operating cash flow: 290166.6866530759
Depreciation & amortization: 1778450.6535555823
Net tangible assets: 14759899.268497422
Owner earnings: 194591.67765919177
Buffett classification: The Gruesome
Stock price: 1.6783829174664107
Shares outstanding: 12962713
Book value: 14771327.49730184
P/B ratio: 1.4728802179217702
Market cap (USD): 21756396.063219767
Debt to equity: 0.8529535688568014
Current ratio: 0.9598808083879597
Quick ratio: 0.41804705105348233
Interest coverage ratio: -0.22528544380056226
COGS to revenue (%): 75.40725159783173
SG&A to revenue (%): 3.02883049751156
Free cash flow (dilution-adjusted): -541179.9976016309
Buyback yield (%): 0
Retained earnings: 4736083.463244993
Inventory turnover: 4.5069185537345176
Receivables turnover: 10.316596944567847
Capitalized R&D asset: 0
ROCI (R&D-adjusted, %): -1.2671136174778739
FCF margin (%): -1.34952601072408
Revenue growth (%): -19.71738880115948
Rule of 40 score: -21.06691481188356
Financial ratios for SHIVATEX.NS — quarterly report dated 2024-09-30
Capital expenditures: 0
Net tangible assets: 15158110.367892977
Buffett classification: The Gruesome
Stock price: 2.2449832775919734
Shares outstanding: 12962713
Book value: 15167677.974199712
P/B ratio: 1.9186241932829227
Market cap (USD): 29101073.917224083
Debt to equity: 0.9059013826960605
Current ratio: 1.1051160463750462
Quick ratio: 0.5357392745017002
Buyback yield (%): 0
Capitalized R&D asset: 0
Rule of 40 score: 0
Financial ratios for SHIVATEX.NS — annual report dated 2025-03-31
Total revenue: 37725906.00888473
Gross profit: 18458300.21042787
Operating income: 2227893.383212532
Net income: 1410182.3708206685
Capital expenditures: 482861.81903203175
Operating cash flow: 1559083.4697217676
Depreciation & amortization: 1678092.1206453121
Net tangible assets: 15842529.810614916
Owner earnings: 2605412.672433949
Return on net tangible assets (%): 16.445685781119714
Capex to operating income (%): 21.67347067280951
Buffett classification: The Great
Stock price: 2.026607538802661
P/E ratio: 18.629031558412546
Shares outstanding: 12962713
Book value: 15860182.370820668
P/B ratio: 1.6563701018638368
Market cap (USD): 26270331.889135256
Debt to equity: 0.7782844886045346
Current ratio: 1.0731522917176521
Quick ratio: 0.4279210222703912
Effective tax rate (%): -23.8724584103512
Interest coverage ratio: 1.607920892323788
COGS to revenue (%): 51.072612527633396
SG&A to revenue (%): 3.0028440624540997
Free cash flow (dilution-adjusted): 1039314.9403787701
Buyback yield (%): 0
Retained earnings: 6027203.647416413
Inventory turnover: 2.232595343948027
Receivables turnover: 7.978347454379584
Capitalized R&D asset: 0
ROCI (R&D-adjusted, %): 10.047921309719076
FCF margin (%): 2.754910485473838
Revenue growth (%): -5.92392242368348
Rule of 40 score: -3.169011938209642
Financial ratios for SHIVATEX.NS — quarterly report dated 2025-03-31
Total revenue: 10705973.813420622
Gross profit: 5359843.34814122
Operating income: 634264.671498714
Net income: 721580.547112462
Capital expenditures: 0
Depreciation & amortization: 413783.02548515314
Net tangible assets: 15842529.810614916
Owner earnings: 1135363.5725976152
Return on net tangible assets (%): 7.166554749588613
Capex to operating income (%): 0
Buffett classification: The Great
Stock price: 2.026607538802661
P/E ratio: 9.101663007082456
Shares outstanding: 12962713
Book value: 15860182.370820668
P/B ratio: 1.6563701018638368
Market cap (USD): 26270331.889135256
Debt to equity: 0.7782844886045346
Current ratio: 1.0731522917176521
Quick ratio: 0.4279210222703912
Effective tax rate (%): -115.92387882180087
Interest coverage ratio: 1.4704048999945798
COGS to revenue (%): 49.935956863425965
Buyback yield (%): 0
Retained earnings: 6027203.647416413
Inventory turnover: 0.6194721912920503
Receivables turnover: 2.264120016119502
Capitalized R&D asset: 0
ROCI (R&D-adjusted, %): 2.860568444062719
Rule of 40 score: 0
Financial ratios for SHIVATEX.NS — quarterly report dated 2025-06-30
Total revenue: 8914462.906622982
Gross profit: 5734226.53873157
Operating income: 630224.6665106483
Net income: 287292.30049145804
Capital expenditures: 0
Depreciation & amortization: 424373.97612918325
Owner earnings: 711666.2766206414
Capex to operating income (%): 0
Buffett classification: The Great
Stock price: 2.3918792417505266
P/E ratio: 26.980573520792596
Shares outstanding: 12962713
Market cap (USD): 31005244.141469695
Effective tax rate (%): 14.93313006721641
Interest coverage ratio: 1.8655697956356079
COGS to revenue (%): 35.67501936127482
Buyback yield (%): 0
Capitalized R&D asset: 0
Revenue growth (%): -16.73375012884738
Rule of 40 score: -16.73375012884738
Financial ratios for SHIVATEX.NS — quarterly report dated 2025-09-30
Total revenue: 11843630.214205185
Gross profit: 5506426.155580608
Operating income: 1086899.6617812852
Net income: 655986.4712514093
Capital expenditures: 0
Depreciation & amortization: 418049.60541149945
Net tangible assets: 16123697.85794814
Owner earnings: 1074036.0766629088
Return on net tangible assets (%): 6.6612267615363745
Capex to operating income (%): 0
Buffett classification: The Great
Stock price: 2.09086809470124
P/E ratio: 16.279647610768595
Shares outstanding: 12962713
Book value: 16140270.574971817
P/B ratio: 1.6792359772764416
Market cap (USD): 27103323.032468997
Debt to equity: 0.7249563787594943
Current ratio: 1.1362714331116717
Quick ratio: 0.6201157340270891
Effective tax rate (%): 17.433874446588714
Interest coverage ratio: 2.8561102058954226
COGS to revenue (%): 53.507277279087695
Buyback yield (%): 0
Inventory turnover: 0.9456635846085517
Receivables turnover: 1.6927623384428963
Capitalized R&D asset: 0
ROCI (R&D-adjusted, %): 5.001460367493828
Revenue growth (%): 32.85859550109277
Rule of 40 score: 32.85859550109277
Financial ratios for SHIVATEX.NS — quarterly report dated 2025-12-31
Total revenue: 8512565.445026178
Gross profit: 4566336.192491924
Operating income: 613022.1677620587
Net income: 181419.18235490698
Capital expenditures: 0
Depreciation & amortization: 415406.0376517768
Owner earnings: 596825.2200066838
Capex to operating income (%): 0
Buffett classification: The Great
Stock price: 2.04945973042219
P/E ratio: 14.389247490617384
Shares outstanding: 12962713
Market cap (USD): 26566558.290520217
Effective tax rate (%): 38.0242027551564
Interest coverage ratio: 1.757561240458625
COGS to revenue (%): 46.357696490192666
Buyback yield (%): 0
Capitalized R&D asset: 0
Revenue growth (%): -28.125369577849078
Rule of 40 score: -28.125369577849078
Financial ratios for SKO.AX — annual report dated 2022-03-31
Total revenue: 12486013.986013986
Gross profit: 12486013.986013986
Operating income: -26014685.314685315
Net income: -25146153.846153848
Capital expenditures: 541258.7412587412
Depreciation & amortization: 5620979.020979022
Net tangible assets: 83093006.99300699
Owner earnings: -20066433.566433568
Return on net tangible assets (%): -24.149365021923366
Buffett classification: The Gruesome
Stock price: 3.263157894736842
Shares outstanding: 126139278
Book value: 105511188.81118882
P/B ratio: 3.901125420723686
Market cap (USD): 411612380.84210527
Debt to equity: 0.019916357924457024
Current ratio: 9.83
Quick ratio: 9.83
Interest coverage ratio: -759.204081632653
COGS to revenue (%): 0
SG&A to revenue (%): 220.1960235228227
Free cash flow (dilution-adjusted): -24160839.160839163
Buyback yield (%): 0.5416189437279869
Retained earnings: -63962937.062937066
Receivables turnover: 3.6342357012008955
Capitalized R&D asset: 0
ROCI (R&D-adjusted, %): -24.173603394610467
FCF margin (%): -193.50322038644637
Rule of 40 score: -193.50322038644637
Financial ratios for SKO.AX — annual report dated 2023-03-31
Total revenue: 29240251.572327044
Gross profit: 29240251.572327044
Operating income: -22840251.572327044
Net income: -19207547.16981132
Capital expenditures: 291194.9685534591
Depreciation & amortization: 8201257.861635219
Net tangible assets: 57162893.081761
Owner earnings: -11297484.27672956
Return on net tangible assets (%): -19.7636677705773
Buffett classification: The Gruesome
Stock price: 1.4362416107382552
Shares outstanding: 126139278
Book value: 79201257.86163522
P/B ratio: 2.2874192241817526
Market cap (USD): 181166479.81208056
Debt to equity: 0.024696259826887952
Current ratio: 8.297582094429016
Quick ratio: 8.297582094429016
Interest coverage ratio: -615.5254237288135
COGS to revenue (%): 0
SG&A to revenue (%): 126.00017207261462
Free cash flow (dilution-adjusted): -22855345.911949683
Buyback yield (%): 0
Retained earnings: -76733962.26415093
Receivables turnover: 3.900990099009901
Capitalized R&D asset: 0
ROCI (R&D-adjusted, %): -28.223261886628226
FCF margin (%): -78.16398520175514
Revenue growth (%): 134.18403667559605
Rule of 40 score: 56.02005147384091
Financial ratios for SKO.AX — annual report dated 2024-03-31
Total revenue: 41174251.49700599
Gross profit: 41174251.49700599
Operating income: -12544910.17964072
Net income: -9508383.233532935
Capital expenditures: 138922.15568862276
Depreciation & amortization: 10163473.053892216
Net tangible assets: 50674850.2994012
Owner earnings: 516167.6646706576
Buffett classification: The Gruesome
Stock price: 2.366013071895425
Shares outstanding: 126139278
Book value: 69297005.98802395
P/B ratio: 4.306783191744665
Market cap (USD): 298447180.627451
Debt to equity: 0.017135302352107563
Current ratio: 7.156217189140543
Quick ratio: 7.156217189140543
Interest coverage ratio: -419
COGS to revenue (%): 0
SG&A to revenue (%): 86.23056674568433
Free cash flow (dilution-adjusted): -3311377.2455089823
Buyback yield (%): 0
Retained earnings: -82552694.61077845
Receivables turnover: 5.4676367684478375
Capitalized R&D asset: 0
ROCI (R&D-adjusted, %): -17.935722480009588
FCF margin (%): -8.042349587702331
Revenue growth (%): 40.81360208259384
Rule of 40 score: 32.771252494891506
Financial ratios for SKO.AX — quarterly report dated 2025-03-31
Capital expenditures: 0
Net tangible assets: 39569142.85714286
Buffett classification: The Gruesome
Stock price: 2.232704402515723
Shares outstanding: 126139278
Book value: 57107428.571428575
P/B ratio: 4.931612723001468
Market cap (USD): 281631721.3207547
Debt to equity: 0.020542736496627908
Current ratio: 3.7341798414871983
Quick ratio: 3.7341798414871983
Buyback yield (%): 0
Retained earnings: -91328000
Capitalized R&D asset: 0
Rule of 40 score: 0
Financial ratios for SKO.AX — annual report dated 2025-03-31
Total revenue: 50561142.85714286
Gross profit: 50561142.85714286
Operating income: -10926285.714285715
Net income: -12549714.285714285
Capital expenditures: 706285.7142857143
Depreciation & amortization: 11375428.57142857
Net tangible assets: 39569142.85714286
Owner earnings: -1880571.4285714289
Return on net tangible assets (%): -4.752621090026862
Buffett classification: The Gruesome
Stock price: 2.232704402515723
Shares outstanding: 126139278
Book value: 57107428.571428575
P/B ratio: 4.931612723001468
Market cap (USD): 281631721.3207547
Debt to equity: 0.020542736496627908
Current ratio: 3.7341798414871983
Quick ratio: 3.7341798414871983
Interest coverage ratio: -398.3541666666667
COGS to revenue (%): 0
SG&A to revenue (%): 80.19032119527135
Free cash flow (dilution-adjusted): -797714.2857142857
Buyback yield (%): 0
Retained earnings: -91328000
Receivables turnover: 3.603274148884183
Capitalized R&D asset: 0
ROCI (R&D-adjusted, %): -18.701890630960182
FCF margin (%): -1.5777220225582602
Revenue growth (%): 22.797964793165555
Rule of 40 score: 21.220242770607296
Financial ratios for SYRMA.NS — annual report dated 2023-03-31
Total revenue: 244801948.84287456
Gross profit: 54944092.570036545
Operating income: 19771741.778319124
Net income: 14990986.601705238
Capital expenditures: 22777.10109622412
Operating cash flow: -8559805.115712546
Depreciation & amortization: 3800121.8026796593
Net tangible assets: 172171254.5676005
Owner earnings: 18768331.303288672
Return on net tangible assets (%): 10.900966802167062
Capex to operating income (%): 0.11520027598782698
Buffett classification: The Great
Stock price: 3.1718635809987825
P/E ratio: 40.75650026046508
Shares outstanding: 192624977
Book value: 187928501.8270402
P/B ratio: 3.2511308470885543
Market cap (USD): 610980149.3370281
Debt to equity: 0.24287102216420714
Current ratio: 1.4254265387437424
Quick ratio: 0.7434324178732968
Effective tax rate (%): 31.120510711628093
Interest coverage ratio: 7.931883703884681
COGS to revenue (%): 77.55569641918895
R&D to revenue (%): 0.0831416084194437
SG&A to revenue (%): 1.5900397248714317
Free cash flow (dilution-adjusted): -23677101.096224118
Buyback yield (%): 0.6501404330972139
Retained earnings: 34674056.02923264
Inventory turnover: 2.6534470930499783
Receivables turnover: 4.996765491951022
Capitalized R&D asset: 316273.93668413046
ROCI (R&D-adjusted, %): 9.679269262614438
FCF margin (%): -9.671941423726654
Rule of 40 score: -9.671941423726654
Financial ratios for SYRMA.NS — annual report dated 2024-03-31
Total revenue: 375376543.9501139
Gross profit: 72899508.33433266
Operating income: 18156133.828996282
Net income: 14910660.75068953
Capital expenditures: 84422.59263700683
Operating cash flow: -13086820.961746013
Depreciation & amortization: 6174001.678858376
Net tangible assets: 152007554.86269337
Owner earnings: 21000239.8369109
Return on net tangible assets (%): 13.8152606006196
Capex to operating income (%): 0.4649811101424005
Buffett classification: The Great
Stock price: 5.552903071017274
P/E ratio: 71.73577645031378
Shares outstanding: 192624977
Book value: 201106727.4253508
P/B ratio: 5.318707335312634
Market cap (USD): 1069627826.3379319
Debt to equity: 0.3755975597321215
Current ratio: 1.2338796060591606
Quick ratio: 0.6894913332147984
Effective tax rate (%): 25.294849225851806
Interest coverage ratio: 4.054305912596401
COGS to revenue (%): 80.57963143695503
R&D to revenue (%): 0.049324897412838846
SG&A to revenue (%): 1.5914627036369127
Free cash flow (dilution-adjusted): -53936563.13706679
Buyback yield (%): 0.09882700868146374
Retained earnings: 44189471.15961146
Inventory turnover: 2.5116638470033066
Receivables turnover: 3.3653480206333195
Capitalized R&D asset: 377050.19510405225
ROCI (R&D-adjusted, %): 8.193402713886472
Rosenberg metric: 88.21900863247821
FCF margin (%): -14.368655688895348
Revenue growth (%): 53.33887075835669
Rule of 40 score: 38.97021506946135
Financial ratios for SYRMA.NS — quarterly report dated 2024-09-30
Capital expenditures: 0
Net tangible assets: 154952580.02866697
Buffett classification: The Gruesome
Stock price: 5.064739608217869
Shares outstanding: 192624977
Book value: 204511944.57716197
P/B ratio: 4.770358780564359
Market cap (USD): 975595350.543956
Debt to equity: 0.3830381725221852
Current ratio: 1.3050616115570133
Quick ratio: 0.8175392462126411
Buyback yield (%): 0
Capitalized R&D asset: 0
Rule of 40 score: 0
Financial ratios for SYRMA.NS — quarterly report dated 2024-12-31
Capital expenditures: 0
Buffett classification: The Gruesome
Stock price: 6.866301433733534
Shares outstanding: 192624977
Market cap (USD): 1322621155.7479892
Buyback yield (%): 0
Capitalized R&D asset: 0
Rule of 40 score: 0
Financial ratios for SYRMA.NS — quarterly report dated 2025-03-31
Total revenue: 108061842.41290623
Gross profit: 29370002.338087443
Operating income: 10140869.768529342
Net income: 8353168.108487257
Capital expenditures: 0
Depreciation & amortization: 2425765.7236380638
Net tangible assets: 164133154.07996258
Owner earnings: 10778933.832125321
Return on net tangible assets (%): 6.567188629589136
Capex to operating income (%): 0
Buffett classification: The Great
Stock price: 5.357101178667289
P/E ratio: 30.8838358669863
Shares outstanding: 192624977
Book value: 213329319.61655366
P/B ratio: 4.837176123667656
Market cap (USD): 1031911491.3274595
Debt to equity: 0.3642010522687455
Current ratio: 1.3286180193603152
Quick ratio: 0.9573204752479899
Effective tax rate (%): 23.47409795332598
Interest coverage ratio: 5.543519938650307
COGS to revenue (%): 72.82111642529271
Buyback yield (%): 0
Retained earnings: 58720598.55038578
Inventory turnover: 0.8190264593011513
Receivables turnover: 0.6256415566976049
Capitalized R&D asset: 0
ROCI (R&D-adjusted, %): 4.356475124725414
Rule of 40 score: 0
Financial ratios for SYRMA.NS — annual report dated 2025-03-31
Total revenue: 442680734.1594575
Gross profit: 99978840.30862753
Operating income: 29021393.500116903
Net income: 21563011.456628475
Capital expenditures: 8483750.29226093
Operating cash flow: 20629296.235679213
Depreciation & amortization: 8775894.31844751
Net tangible assets: 164133154.07996258
Owner earnings: 21855155.482815057
Return on net tangible assets (%): 13.315503260339248
Capex to operating income (%): 29.232746154063054
Buffett classification: The Good
Stock price: 5.357101178667289
P/E ratio: 47.855629692681426
Shares outstanding: 192624977
Book value: 213329319.61655366
P/B ratio: 4.837176123667656
Market cap (USD): 1031911491.3274595
Debt to equity: 0.3642010522687455
Current ratio: 1.3286180193603152
Quick ratio: 0.9573204752479899
Effective tax rate (%): 22.197616787936305
Interest coverage ratio: 4.246476223058502
COGS to revenue (%): 77.41513632878944
R&D to revenue (%): 0.06623196875583458
SG&A to revenue (%): 1.6001305625412794
Free cash flow (dilution-adjusted): -8551905.541267242
Buyback yield (%): 0
Retained earnings: 58720598.55038578
Inventory turnover: 3.5668490970547513
Receivables turnover: 2.562971882168125
Capitalized R&D asset: 484415.0609751471
ROCI (R&D-adjusted, %): 12.469830106785713
Rosenberg metric: 146.2529464596146
FCF margin (%): -1.931844980221518
Revenue growth (%): 17.929780454872557
Rule of 40 score: 15.997935474651038
Financial ratios for SYRMA.NS — quarterly report dated 2025-06-30
Total revenue: 110458694.12590687
Gross profit: 27301310.55464545
Operating income: 7727357.828223731
Net income: 5841329.27685467
Capital expenditures: 0
Depreciation & amortization: 2408144.1610109997
Owner earnings: 8249473.437865669
Capex to operating income (%): 0
Buffett classification: The Great
Stock price: 6.624736718932835
P/E ratio: 89.90031302082299
Shares outstanding: 192624977
Market cap (USD): 1276089758.1154928
Effective tax rate (%): 25.655651034297883
Interest coverage ratio: 4.422582373426199
COGS to revenue (%): 75.28369245111125
Buyback yield (%): 0
Capitalized R&D asset: 0
Revenue growth (%): 2.2180370605215365
Rule of 40 score: 2.2180370605215365
Financial ratios for SYRMA.NS — quarterly report dated 2025-09-30
Total revenue: 129186809.470124
Gross profit: 30760541.149943627
Operating income: 10528523.111612175
Net income: 7479255.918827509
Capital expenditures: 0
Depreciation & amortization: 2463246.8996617813
Net tangible assets: 278123449.83089066
Owner earnings: 9942502.81848929
Return on net tangible assets (%): 3.574852399010116
Capex to operating income (%): 0
Buffett classification: The Great
Stock price: 8.65163472378805
P/E ratio: 76.89120182804155
Shares outstanding: 192624977
Book value: 325509131.9052987
P/B ratio: 5.119736364775536
Market cap (USD): 1666520939.6820743
Debt to equity: 0.11483320206728442
Current ratio: 1.8009768404112585
Quick ratio: 1.3951857436296828
Effective tax rate (%): 25.87597765363128
Interest coverage ratio: 7.393555537962156
COGS to revenue (%): 76.18910067048496
Buyback yield (%): 0
Inventory turnover: 0.9926447681095155
Receivables turnover: 0.6041916900159341
Capitalized R&D asset: 0
ROCI (R&D-adjusted, %): 3.069635106938267
Revenue growth (%): 16.954858549087863
Rule of 40 score: 16.954858549087863
Financial ratios for SYRMA.NS — quarterly report dated 2025-12-31
Total revenue: 140824328.84036985
Gross profit: 38635178.79024173
Operating income: 15497048.011585163
Net income: 12288515.094129443
Capital expenditures: 0
Depreciation & amortization: 2259440.7931380193
Owner earnings: 14547955.887267463
Capex to operating income (%): 0
Buffett classification: The Great
Stock price: 8.16698228806951
P/E ratio: 46.32095703824055
Shares outstanding: 192624977
Market cap (USD): 1573164775.3987968
Effective tax rate (%): 20.263393760661522
Interest coverage ratio: 18.10947669877636
COGS to revenue (%): 72.5649828347229
Buyback yield (%): 0
Capitalized R&D asset: 0
Revenue growth (%): 9.008287624703016
Rule of 40 score: 9.008287624703016
Financial ratios for UVSP — annual report dated 2021-12-31
Capital expenditures: 0
Buffett classification: The Gruesome
Stock price: 25.76
Shares outstanding: 27845802
Market cap (USD): 717307859.5200001
Buyback yield (%): 0
Capitalized R&D asset: 0
Rule of 40 score: 0
Financial ratios for UVSP — annual report dated 2022-12-31
Total revenue: 296182000
Net income: 78120000
Capital expenditures: 1624000
Operating cash flow: 109455000
Depreciation & amortization: 4465000
Net tangible assets: 589606000
Owner earnings: 80961000
Return on net tangible assets (%): 13.731373154275905
Buffett classification: The Gruesome
Stock price: 23.2
P/E ratio: 8.26961861751152
Shares outstanding: 27845802
Book value: 776500000
P/B ratio: 0.8319672973599485
Market cap (USD): 646022606.4
Debt to equity: 0.5169517063747585
Effective tax rate (%): 19.637897335665055
COGS to revenue (%): 0
SG&A to revenue (%): 40.96906631733191
Free cash flow (dilution-adjusted): 100114000
Buyback yield (%): 1.9014814463619676
Retained earnings: 428637000
Receivables turnover: 1.2366422412893259
Capitalized R&D asset: 0
FCF margin (%): 33.80151393400004
Rule of 40 score: 33.80151393400004
Financial ratios for UVSP — annual report dated 2023-12-31
Total revenue: 296821000
Net income: 71104000
Capital expenditures: 4847000
Operating cash flow: 89741000
Depreciation & amortization: 5057000
Net tangible assets: 652748000
Owner earnings: 71314000
Return on net tangible assets (%): 10.925196247250089
Buffett classification: The Gruesome
Stock price: 20.39
P/E ratio: 7.985147147558505
Shares outstanding: 27845802
Book value: 839208000
P/B ratio: 0.6765615947178769
Market cap (USD): 567775902.78
Debt to equity: 0.5881879105060962
Effective tax rate (%): 19.827712568638724
COGS to revenue (%): 0
SG&A to revenue (%): 42.8517524029634
Free cash flow (dilution-adjusted): 78823000
Buyback yield (%): 0.29835714966163085
Retained earnings: 474691000
Receivables turnover: 1.0693708883652897
Capitalized R&D asset: 0
FCF margin (%): 26.555735611698633
Revenue growth (%): 0.21574572391299943
Rule of 40 score: 26.771481335611632
Financial ratios for UVSP — quarterly report dated 2024-09-30
Capital expenditures: 0
Buffett classification: The Gruesome
Stock price: 26.79
Shares outstanding: 27845802
Market cap (USD): 745989035.5799999
Buyback yield (%): 0
Capitalized R&D asset: 0
Rule of 40 score: 0
Financial ratios for UVSP — annual report dated 2024-12-31
Total revenue: 299225000
Net income: 75931000
Capital expenditures: 737000
Operating cash flow: 75106000
Depreciation & amortization: 7466000
Net tangible assets: 703482000
Owner earnings: 82660000
Return on net tangible assets (%): 11.750122959791437
Buffett classification: The Gruesome
Stock price: 28.31
P/E ratio: 10.381986996351952
Shares outstanding: 27845802
Book value: 887301000
P/B ratio: 0.8884410753735204
Market cap (USD): 788314654.62
Debt to equity: 0.45728112557069134
Effective tax rate (%): 20.32423924449108
COGS to revenue (%): 0
SG&A to revenue (%): 43.5625365527613
Free cash flow (dilution-adjusted): 67387000
Buyback yield (%): 2.505979038220813
Retained earnings: 525780000
Receivables turnover: 1.073191113916605
Capitalized R&D asset: 0
FCF margin (%): 22.520511320912355
Revenue growth (%): 0.8099157404631074
Rule of 40 score: 23.330427061375463
Financial ratios for UVSP — quarterly report dated 2024-12-31
Capital expenditures: 0
Buffett classification: The Gruesome
Stock price: 28.31
Shares outstanding: 27845802
Market cap (USD): 788314654.62
Buyback yield (%): 0
Capitalized R&D asset: 0
Rule of 40 score: 0
Financial ratios for UVSP — quarterly report dated 2025-03-31
Total revenue: 79196000
Net income: 22395000
Capital expenditures: 1865000
Operating cash flow: 15603000
Depreciation & amortization: 1469000
Net tangible assets: 719901000
Owner earnings: 21999000
Return on net tangible assets (%): 3.055836844232749
Buffett classification: The Gruesome
Stock price: 27.39
P/E ratio: 8.51413838780978
Shares outstanding: 27845802
Book value: 903472000
P/B ratio: 0.8441839003090301
Market cap (USD): 762696516.78
Debt to equity: 0.3923176368498415
Effective tax rate (%): 18.73208259244475
COGS to revenue (%): 0
SG&A to revenue (%): 40.82276882670842
Free cash flow (dilution-adjusted): 12588000
Buyback yield (%): 1.0645125317049178
Retained earnings: 541776000
Receivables turnover: 0.3398401125991787
Capitalized R&D asset: 0
FCF margin (%): 15.894742158694882
Rule of 40 score: 15.894742158694882
Financial ratios for UVSP — quarterly report dated 2025-06-30
Total revenue: 81042000
Net income: 19978000
Capital expenditures: 1123000
Operating cash flow: 23255000
Depreciation & amortization: 1380000
Net tangible assets: 733256000
Owner earnings: 20235000
Return on net tangible assets (%): 2.759609195151489
Buffett classification: The Gruesome
Stock price: 29.23
P/E ratio: 19.20876011752767
Shares outstanding: 27845802
Book value: 916733000
P/B ratio: 0.8878624337293411
Market cap (USD): 813932792.46
Debt to equity: 0.4140976707503711
Effective tax rate (%): 20.139110968979853
COGS to revenue (%): 0
SG&A to revenue (%): 40.85289109350707
Free cash flow (dilution-adjusted): 20725000
Buyback yield (%): 0.6023838878860447
Retained earnings: 555403000
Receivables turnover: 0.35251898701140527
Capitalized R&D asset: 0
FCF margin (%): 25.573159596258733
Revenue growth (%): 2.3309258043335523
Rule of 40 score: 27.904085400592287
Financial ratios for UVSP — quarterly report dated 2025-09-30
Total revenue: 83247000
Net income: 25639000
Capital expenditures: 500000
Operating cash flow: 31984000
Depreciation & amortization: 1719000
Net tangible assets: 750172000
Owner earnings: 26858000
Return on net tangible assets (%): 3.580245597009753
Buffett classification: The Gruesome
Stock price: 29.43
P/E ratio: 12.049372946832912
Shares outstanding: 27845802
Book value: 933219000
P/B ratio: 0.8781453794446963
Market cap (USD): 819501952.86
Debt to equity: 0.3845903266007229
Effective tax rate (%): 20.030566732166807
COGS to revenue (%): 0
SG&A to revenue (%): 39.84527970977933
Free cash flow (dilution-adjusted): 30212000
Buyback yield (%): 0.9496011538278105
Retained earnings: 574715000
Receivables turnover: 0.364486963374855
Capitalized R&D asset: 0
FCF margin (%): 36.291998510456835
Revenue growth (%): 2.720811431109795
Rule of 40 score: 39.01280994156663
Financial ratios for UVSP — annual report dated 2025-12-31
Total revenue: 328056000
Net income: 90757000
Capital expenditures: 4174000
Operating cash flow: 101512000
Depreciation & amortization: 6017000
Net tangible assets: 760480000
Owner earnings: 92600000
Return on net tangible assets (%): 12.176520092573112
Buffett classification: The Gruesome
Stock price: 32.34
P/E ratio: 9.92246588891215
Shares outstanding: 27845802
Book value: 943318000
P/B ratio: 0.9546443899936183
Market cap (USD): 900533236.6800001
Debt to equity: 0.3470706590990525
Effective tax rate (%): 19.932068813409792
COGS to revenue (%): 0
SG&A to revenue (%): 40.60343356012388
Free cash flow (dilution-adjusted): 92237000
Buyback yield (%): 4.023838157666609
Retained earnings: 591202000
Receivables turnover: 1.233706014418358
Capitalized R&D asset: 0
FCF margin (%): 28.11623625234716
Revenue growth (%): 9.635224329517921
Rule of 40 score: 37.75146058186508
Financial ratios for UVSP — quarterly report dated 2025-12-31
Total revenue: 84571000
Net income: 22745000
Capital expenditures: 670000
Operating cash flow: 30670000
Depreciation & amortization: 1486000
Net tangible assets: 760480000
Owner earnings: 23561000
Return on net tangible assets (%): 3.098174836945087
Buffett classification: The Gruesome
Stock price: 32.34
P/E ratio: 9.92246588891215
Shares outstanding: 27845802
Book value: 943318000
P/B ratio: 0.9546443899936183
Market cap (USD): 900533236.6800001
Debt to equity: 0.3470706590990525
Effective tax rate (%): 20.79328597297674
COGS to revenue (%): 0
SG&A to revenue (%): 40.90527485781178
Free cash flow (dilution-adjusted): 28712000
Buyback yield (%): 1.7136513536016977
Retained earnings: 591202000
Receivables turnover: 0.3180425029427139
Capitalized R&D asset: 0
FCF margin (%): 33.95017204479077
Revenue growth (%): 1.5904477038211586
Rule of 40 score: 35.540619748611924
Financial ratios for VIPIND.NS — annual report dated 2022-03-31
Capital expenditures: 0
Buffett classification: The Gruesome
Stock price: 9.735197151523144
Shares outstanding: 142053696
Market cap (USD): 1382920736.6625345
Buyback yield (%): 0
Retained earnings: 35387049.98021891
Capitalized R&D asset: 0
Rule of 40 score: 0
Financial ratios for VIPIND.NS — annual report dated 2023-03-31
Total revenue: 253191230.20706457
Gross profit: 124286236.29719855
Operating income: 31069427.527405605
Net income: 18555420.219244823
Capital expenditures: 12885505.481120586
Operating cash flow: 21302070.645554204
Depreciation & amortization: 8971985.383678442
Net tangible assets: 77903775.88306943
Owner earnings: 14641900.12180268
Return on net tangible assets (%): 18.79485295267281
Capex to operating income (%): 41.47326328994826
Buffett classification: The Good
Stock price: 6.95006090133983
P/E ratio: 53.20719373611658
Shares outstanding: 142053696
Book value: 78159561.51035322
P/B ratio: 12.631619463853264
Market cap (USD): 987281838.4604142
Debt to equity: 0.5489566613162119
Current ratio: 1.6162913272640154
Quick ratio: 0.6785657243251877
Effective tax rate (%): 22.48511677606472
Interest coverage ratio: 10.02278978388998
COGS to revenue (%): 50.91210852936931
SG&A to revenue (%): 13.497859238947422
Free cash flow (dilution-adjusted): 7483556.638246042
Buyback yield (%): 0
Retained earnings: 43468940.31668697
Inventory turnover: 1.8025753265997853
Receivables turnover: 8.13995379253632
Capitalized R&D asset: 0
ROCI (R&D-adjusted, %): 32.32092852346017
FCF margin (%): 2.9556934622600664
Rule of 40 score: 2.9556934622600664
Financial ratios for VIPIND.NS — annual report dated 2024-03-31
Total revenue: 269212135.7476916
Gross profit: 135004197.14594075
Operating income: 12477515.28960307
Net income: 6511572.130950953
Capital expenditures: 11886317.30423312
Operating cash flow: -15793260.582803693
Depreciation & amortization: 11930687.13274973
Net tangible assets: 80988128.07291041
Owner earnings: 6555941.959467562
Return on net tangible assets (%): 8.094941956882256
Capex to operating income (%): 95.26189332051898
Buffett classification: The Gruesome
Stock price: 6.303982725527831
P/E ratio: 137.52501357158462
Shares outstanding: 142053696
Book value: 81293920.1343087
P/B ratio: 11.015633693170248
Market cap (USD): 895504045.681382
Debt to equity: 1.285052588101665
Current ratio: 1.314573122602199
Quick ratio: 0.47416340841088883
Effective tax rate (%): 29.09375816139984
Interest coverage ratio: 2.2482713915298183
COGS to revenue (%): 49.534067422136694
SG&A to revenue (%): 19.59188582424631
Free cash flow (dilution-adjusted): -28761242.355198465
Buyback yield (%): 0
Retained earnings: 46161410.241036095
Inventory turnover: 1.2144464102396086
Receivables turnover: 6.85358407619978
Capitalized R&D asset: 0
ROCI (R&D-adjusted, %): 10.649948822927326
FCF margin (%): -10.683486565462191
Revenue growth (%): 6.32759101787404
Rule of 40 score: -4.355895547588151
Financial ratios for VIPIND.NS — quarterly report dated 2024-09-30
Capital expenditures: 0
Net tangible assets: 77108217.86908744
Buffett classification: The Gruesome
Stock price: 6.426779741997133
Shares outstanding: 142053696
Book value: 77434304.82560918
P/B ratio: 11.789965930277038
Market cap (USD): 912947815.7286191
Debt to equity: 1.2840902079348429
Current ratio: 1.3040345258553352
Quick ratio: 0.5792454304014998
Buyback yield (%): 0
Capitalized R&D asset: 0
Rule of 40 score: 0
Financial ratios for VIPIND.NS — annual report dated 2025-03-31
Total revenue: 254667991.58288518
Gross profit: 116173719.89712414
Operating income: -4298573.766658872
Net income: -8041851.76525602
Capital expenditures: 4810614.916997896
Operating cash flow: 34122048.164601356
Depreciation & amortization: 13918634.556932429
Net tangible assets: 71769932.1954641
Owner earnings: 1066167.874678513
Buffett classification: The Gruesome
Stock price: 3.264091492589567
Shares outstanding: 142053696
Book value: 72031797.98924482
P/B ratio: 6.437105188929711
Market cap (USD): 463676260.6045046
Debt to equity: 1.2190015580368732
Current ratio: 1.277355486911326
Quick ratio: 0.5410371838529092
Interest coverage ratio: -0.5023224043715847
COGS to revenue (%): 54.38228448928816
SG&A to revenue (%): 17.20780562147969
Free cash flow (dilution-adjusted): 27854804.769698385
Buyback yield (%): 0
Retained earnings: 37158054.7112462
Inventory turnover: 1.6962286303370464
Receivables turnover: 5.91418254873215
Capitalized R&D asset: 0
ROCI (R&D-adjusted, %): -4.050273175890024
FCF margin (%): 10.937693660113018
Revenue growth (%): -5.402484596176348
Rule of 40 score: 5.53520906393667
Financial ratios for VIPIND.NS — quarterly report dated 2025-03-31
Total revenue: 57775309.79658639
Gross profit: 27087912.087912086
Operating income: -2781155.015197568
Net income: -3198503.6240355386
Capital expenditures: 0
Depreciation & amortization: 3541033.4346504556
Net tangible assets: 71769932.1954641
Owner earnings: 342529.81061491696
Buffett classification: The Gruesome
Stock price: 3.264091492589567
Shares outstanding: 142053696
Book value: 72031797.98924482
P/B ratio: 6.437105188929711
Market cap (USD): 463676260.6045046
Debt to equity: 1.2190015580368732
Current ratio: 1.277355486911326
Quick ratio: 0.5410371838529092
Interest coverage ratio: -1.4093601895734598
COGS to revenue (%): 53.11507254001335
Buyback yield (%): 0
Retained earnings: 37158054.7112462
Inventory turnover: 0.3758483434036826
Receivables turnover: 1.3417223217679317
Capitalized R&D asset: 0
ROCI (R&D-adjusted, %): -2.6205058160028196
Rule of 40 score: 0
Financial ratios for VIPIND.NS — quarterly report dated 2025-06-30
Total revenue: 65695062.01731805
Gross profit: 29572899.602153055
Operating income: -812075.8249473438
Net income: -1532880.8799438335
Capital expenditures: 0
Depreciation & amortization: 3696466.1830095956
Owner earnings: 2163585.303065762
Buffett classification: The Gruesome
Stock price: 4.92803650830798
Shares outstanding: 142053696
Market cap (USD): 700045800.0280833
Interest coverage ratio: -0.41656662665066024
COGS to revenue (%): 54.98459291452185
Buyback yield (%): 0
Capitalized R&D asset: 0
Revenue growth (%): 13.707848990538157
Rule of 40 score: 13.707848990538157
Financial ratios for VIPIND.NS — quarterly report dated 2025-09-30
Total revenue: 45810597.51972942
Gross profit: 14029312.288613303
Operating income: -15713641.488162344
Net income: -16137542.277339345
Capital expenditures: 0
Depreciation & amortization: 3719278.4667418264
Net tangible assets: 52107102.59301014
Owner earnings: -12418263.810597518
Return on net tangible assets (%): -23.832190224799323
Buffett classification: The Gruesome
Stock price: 4.689402480270575
Shares outstanding: 142053696
Book value: 52294250.28184891
P/B ratio: 12.73843588470411
Market cap (USD): 666146954.3540022
Debt to equity: 1.6783874097229716
Current ratio: 1.1176874856821541
Quick ratio: 0.5019159880875523
Interest coverage ratio: -7.919318181818182
COGS to revenue (%): 69.37539991140424
Buyback yield (%): 0
Inventory turnover: 0.4767058425636256
Receivables turnover: 1.2014073679853348
Capitalized R&D asset: 0
ROCI (R&D-adjusted, %): -18.297341647522153
Revenue growth (%): -30.26782209650222
Rule of 40 score: -30.26782209650222
Financial ratios for VIPIND.NS — quarterly report dated 2025-12-31
Total revenue: 50588169.767182805
Gross profit: 14902528.68441573
Operating income: -12120975.827113736
Net income: -5889495.377074746
Capital expenditures: 0
Depreciation & amortization: 3562437.339868553
Owner earnings: -2327058.0372061934
Buffett classification: The Gruesome
Stock price: 4.2608889383981285
Shares outstanding: 142053696
Market cap (USD): 605275021.9449705
Interest coverage ratio: -6.817669172932332
COGS to revenue (%): 70.54147490806596
Buyback yield (%): 0
Capitalized R&D asset: 0
Revenue growth (%): 10.428967326601251
Rule of 40 score: 10.428967326601251
Financial ratios for WPRT.TO — annual report dated 2021-12-31
Capital expenditures: 0
Buffett classification: The Gruesome
Stock price: 23.700787401574804
Shares outstanding: 18995734
Market cap (USD): 450213853.07086617
Buyback yield (%): 0
Capitalized R&D asset: 0
Rule of 40 score: 0
Financial ratios for WPRT.TO — annual report dated 2022-12-31
Total revenue: 224777941.17647058
Gross profit: 26619117.647058822
Operating income: -32224999.999999996
Net income: -24040441.176470585
Capital expenditures: 10472058.823529411
Operating cash flow: -25452205.88235294
Depreciation & amortization: 8676470.588235293
Net tangible assets: 142052205.88235292
Owner earnings: -25836029.411764704
Return on net tangible assets (%): -18.18770025518787
Buffett classification: The Gruesome
Stock price: 7.647058823529411
Shares outstanding: 18995734
Book value: 149974999.99999997
P/B ratio: 0.96857139719365
Market cap (USD): 145261495.29411763
Debt to equity: 0.3746849965190277
Current ratio: 2.045609840686546
Quick ratio: 1.4432219836332916
Interest coverage ratio: -13.078484034616531
COGS to revenue (%): 88.15759344189364
R&D to revenue (%): 7.686344038888053
SG&A to revenue (%): 17.04787077442443
Free cash flow (dilution-adjusted): -37654411.76470588
Buyback yield (%): 0
Retained earnings: -753467647.0588235
Inventory turnover: 3.301231089606174
Receivables turnover: 3.007654466745376
Capitalized R&D asset: 17277205.88235294
ROCI (R&D-adjusted, %): -9.53235238698074
FCF margin (%): -16.75182696648326
Rule of 40 score: -16.75182696648326
Financial ratios for WPRT.TO — annual report dated 2023-12-31
Total revenue: 51631818.18181818
Gross profit: 272727.2727272727
Operating income: -33770454.54545455
Net income: -37665151.515151516
Capital expenditures: 4909848.484848484
Operating cash flow: -30303787.87878788
Depreciation & amortization: 8777272.727272727
Net tangible assets: 114060606.06060606
Owner earnings: -33797727.27272727
Return on net tangible assets (%): -29.631376195536664
Buffett classification: The Gruesome
Stock price: 6.606060606060606
Shares outstanding: 18995734
Book value: 121551515.15151513
P/B ratio: 1.0323768478260873
Market cap (USD): 125486970.06060606
Debt to equity: 0.5162295572397289
Current ratio: 1.6077411986324228
Quick ratio: 1.1069142742718985
Interest coverage ratio: -25.856728538283065
COGS to revenue (%): 99.47178448807114
R&D to revenue (%): 18.833817530885934
SG&A to revenue (%): 45.408926842151594
Free cash flow (dilution-adjusted): -36173484.848484844
Buyback yield (%): 0
Retained earnings: -813965151.5151515
Inventory turnover: 1.0039093736117282
Receivables turnover: 0.7738001975544125
Capitalized R&D asset: 21299970.365418896
ROCI (R&D-adjusted, %): -17.516833157478885
Rosenberg metric: -1.5249219436136914
FCF margin (%): -70.06045133080963
Revenue growth (%): -77.02985537122495
Rule of 40 score: -147.09030670203458
Financial ratios for WPRT.TO — quarterly report dated 2024-09-30
Capital expenditures: 0
Buffett classification: The Gruesome
Stock price: 4.592592592592593
Shares outstanding: 18995734
Market cap (USD): 87239667.25925925
Buyback yield (%): 0
Capitalized R&D asset: 0
Rule of 40 score: 0
Financial ratios for WPRT.TO — quarterly report dated 2024-12-31
Capital expenditures: 0
Buffett classification: The Gruesome
Stock price: 3.594405594405594
Shares outstanding: 18995734
Market cap (USD): 68278372.55944055
Buyback yield (%): 0
Capitalized R&D asset: 0
Rule of 40 score: 0